Cellectis SA (CLLS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $118.86M
Last updated: Nov 17, 2026 at 10:55 AM ET
Cellectis SA (CLLS) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Cellectis SA reported EPS of $0.01, above the -$0.21 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CLLS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
CLLS Earnings Call
The latest CLLS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CLLS beat 18, missed 20 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 218.18% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.01 | -$0.21 | -$0.23 - -$0.07 | +104.76% | Beat | -50.0% | 5 | 5 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.22 | -$0.25 | -$0.38 - -$0.17 | +12.00% | Beat | N/A | 6 | 2 up, 1 down | Aug 6, 2026 | $5.22M |
| Mar 31, 2026 | -$0.18 | -$0.26 | -$0.34 - -$0.20 | +30.77% | Beat | N/A | 5 | 3 up, 1 down | May 11, 2026 | $5.80M |
| Dec 31, 2025 | -$0.24 | -$0.29 | N/A | +18.59% | Beat | N/A | 1 | 0 up, 0 down | Mar 19, 2026 | $10.40M |
| Sep 30, 2025 | $0.02 | -$0.10 | -$0.10 - -$0.10 | +120.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 7, 2025 | $35.17M |
| Jun 30, 2025 | -$0.22 | -$0.15 | -$0.15 - -$0.15 | -46.67% | Miss | N/A | 1 | 0 up, 0 down | Aug 4, 2025 | $16.73M |
| Mar 31, 2025 | -$0.17 | -$0.16 | N/A | -6.25% | Miss | N/A | 1 | 0 up, 0 down | May 12, 2025 | $10.65M |
| Dec 31, 2024 | -$0.16 | -$0.09 | N/A | -77.78% | Miss | N/A | 1 | 1 up, 0 down | Mar 13, 2025 | $12.72M |
| Sep 30, 2024 | -$0.22 | -$0.24 | -$0.31 - -$0.03 | +8.33% | Beat | N/A | 6 | 0 up, 0 down | Nov 4, 2024 | $16.20M |
| Jun 30, 2024 | -$0.27 | -$0.27 | -$0.36 - -$0.20 | 0.00% | In line | N/A | 8 | 0 up, 0 down | Aug 6, 2024 | $8.06M |
| Mar 31, 2024 | -$0.14 | -$0.27 | -$0.50 - -$0.15 | +48.15% | Beat | N/A | 5 | 2 up, 0 down | Apr 29, 2024 | $4.53M |
| Dec 31, 2023 | -$0.70 | -$0.22 | -$0.68 - $0.27 | -218.18% | Miss | N/A | 8 | 0 up, 0 down | Mar 13, 2024 | $285392 |
| Sep 30, 2023 | -$0.37 | -$0.36 | -$0.64 - -$0.25 | -2.78% | Miss | N/A | 7 | 0 up, 0 down | Nov 6, 2023 | $155000 |
| Jun 30, 2023 | -$0.15 | -$0.34 | -$0.72 - -$0.29 | +55.88% | Beat | N/A | 7 | 0 up, 0 down | Aug 3, 2023 | $177782 |
| Mar 31, 2023 | -$0.55 | -$0.42 | -$0.72 - -$0.25 | -30.95% | Miss | N/A | 7 | 0 up, 0 down | May 4, 2023 | $139612 |
| Dec 31, 2022 | -$0.59 | -$0.71 | -$1.02 - -$0.24 | +16.90% | Beat | N/A | 8 | 0 up, 0 down | Mar 8, 2023 | $16.17M |
| Sep 30, 2022 | -$0.63 | -$0.21 | -$0.88 - -$0.02 | -200.00% | Miss | N/A | 8 | 0 up, 0 down | Nov 3, 2022 | $176000 |
| Jun 30, 2022 | -$0.42 | -$0.57 | -$0.85 - $0.09 | +26.32% | Beat | N/A | 8 | 0 up, 0 down | Aug 4, 2022 | $1.31M |
| Mar 31, 2022 | -$0.70 | -$0.66 | -$0.96 - -$0.30 | -6.06% | Miss | N/A | 9 | 0 up, 0 down | May 12, 2022 | $1.67M |
| Dec 31, 2021 | -$0.55 | -$0.92 | -$1.10 - -$0.72 | +40.22% | Beat | N/A | 8 | 0 up, 0 down | Mar 3, 2022 | $12.21M |
| Sep 30, 2021 | -$0.82 | -$0.75 | -$0.93 - -$0.55 | -9.33% | Miss | N/A | 8 | 2 up, 0 down | Nov 4, 2021 | $8.31M |
| Jun 30, 2021 | -$0.88 | -$0.65 | -$0.92 - -$0.60 | -35.38% | Miss | N/A | 8 | N/A | Aug 5, 2021 | $11.18M |
| Mar 31, 2021 | -$0.28 | -$0.72 | -$1.05 - -$0.28 | +61.11% | Beat | -159.6% | 9 | N/A | May 6, 2021 | $25.60M |
| Dec 31, 2020 | -$0.95 | -$0.78 | -$1.18 - -$0.45 | -21.79% | Miss | N/A | 9 | N/A | Mar 4, 2021 | $13.91M |
| Sep 30, 2020 | -$0.71 | -$0.50 | -$0.90 - $0.35 | -42.00% | Miss | N/A | 9 | N/A | Nov 5, 2020 | $6.18M |
| Jun 30, 2020 | -$0.76 | -$0.74 | -$0.87 - -$0.64 | -2.70% | Miss | N/A | 9 | N/A | Aug 5, 2020 | $2.90M |
| Mar 31, 2020 | $0.47 | -$0.65 | -$0.84 - -$0.28 | +172.31% | Beat | N/A | 9 | N/A | May 6, 2020 | $50.13M |
| Dec 31, 2019 | -$0.88 | -$0.73 | -$0.95 - -$0.51 | -20.55% | Miss | N/A | 10 | N/A | Mar 4, 2020 | $4.43M |
| Sep 30, 2019 | -$0.23 | -$0.42 | N/A | +45.24% | Beat | N/A | 10 | N/A | Nov 6, 2019 | $8.49M |
| Jun 30, 2019 | -$0.65 | -$0.36 | N/A | -80.56% | Miss | -2266.7% | 8 | N/A | Aug 6, 2019 | $1.15M |
| Mar 31, 2019 | -$0.26 | -$0.32 | N/A | +18.75% | Beat | N/A | 7 | N/A | May 7, 2019 | $1.04M |
| Dec 31, 2018 | -$0.53 | -$0.71 | -$0.86 - -$0.52 | +25.35% | Beat | N/A | 7 | N/A | Mar 11, 2019 | $968000 |
| Sep 30, 2018 | -$0.36 | -$0.31 | N/A | -16.13% | Miss | N/A | 6 | N/A | Nov 13, 2018 | $905000 |
| Jun 30, 2018 | $0.03 | -$0.34 | N/A | +108.82% | Beat | N/A | 6 | N/A | Aug 1, 2018 | $5.05M |
| Mar 31, 2018 | -$0.39 | -$0.38 | N/A | -2.63% | Miss | N/A | 6 | N/A | May 7, 2018 | $6.04M |
| Dec 31, 2017 | -$0.76 | -$0.72 | -$0.87 - -$0.64 | -5.56% | Miss | N/A | 5 | N/A | Mar 12, 2018 | $5.72M |
| Sep 30, 2017 | -$0.37 | -$0.34 | N/A | -8.82% | Miss | N/A | N/A | N/A | Nov 13, 2017 | $6.12M |
| Jun 30, 2017 | -$0.43 | -$0.22 | N/A | -95.45% | Miss | N/A | N/A | N/A | Aug 2, 2017 | $6.75M |
| Mar 31, 2017 | -$0.17 | -$0.37 | N/A | +54.05% | Beat | N/A | N/A | N/A | May 9, 2017 | $6.76M |
| Dec 31, 2016 | -$0.38 | -$0.38 | N/A | 0.00% | In line | -158.5% | N/A | N/A | Mar 6, 2017 | $7.99M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.61, after -$0.79 the year before. It was -$1.12 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.61 | N/A |
| Dec 31, 2024 | -$0.79 | N/A |
| Dec 31, 2023 | -$1.77 | N/A |
| Dec 31, 2022 | -$2.34 | N/A |
| Dec 31, 2021 | -$2.53 | N/A |
| Dec 31, 2020 | -$1.95 | N/A |
| Dec 31, 2019 | -$2.02 | N/A |
| Dec 31, 2018 | -$1.25 | N/A |
| Dec 31, 2017 | -$1.73 | N/A |
| Dec 31, 2016 | -$1.12 | N/A |
Earnings Calls
The 4 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,000 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,974 | 9 | |
| 2025Q2 | Jun 30, 2025 | 4,442 | 10 | |
| 2024Q4 | Dec 31, 2024 | 4,855 | 10 | |
| 2024Q3 | Sep 30, 2024 | 3,552 | 11 |
2026Q3 Earnings Call
Opening remarks
Arthur Stril CFO and Chief Business Officer Good morning, and welcome, everyone, to Cellectis Third Quarter 2026 Business Update and Financial Results Conference Call. Joining me on the call today are Dr. André Choulika, our Chief Executive Officer, and Dr. Adrian Kilcoyne, our Chief Medical Officer. Yesterday evening, Cellectis issued a 6-K and press release reporting our financial statements for the nine-month period ended September 30, 2026, and a business update. The report and press release are available on our website at cellectis.com. As a reminder, please note that this presentation contains forward-looking statements within the meaning of applicable securities laws, including statements regarding our strategy, development programs, financial condition, and expected cash runway. These forward-looking statements are based on current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. For a discussion of these risks and uncertainties, please refer to our filings with the U.S. Securities and Exchange Commission and our annual financial report prepared in French. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements contained in this presentation. I would now like to turn the call over to André.
André Choulika CEO Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Two months ago, we announced the strategic transformation of Cellectis into an in vivo gene editing company. Since September, our team has been fully committed to this new chapter. We're starting with severe dyslipidemias, where the unmet medical need remains high. In severe hypertriglyceridemia, persistently elevated triglyceride levels can expose patients to serious complications, including acute pancreatitis. In severe hypercholesterolemia, prolonged exposure to very high LDL cholesterol substantially increases the risk of cardiovascular disease. For many of these patients, treatment can mean daily pills or repeated injections over the long term, without always achieving sufficient lipid control. Our approach is different: a single injection designed to deliver a potential long-lasting effect. This is what HEAL-101 and HEAL-201 are being developed to achieve. Let me start with HEAL-101, our in vivo base editing candidate targeting the APOC3 gene for severe hypertriglyceridemia. At the European Society of Gene and Cell Therapy in October, we presented an expanded preclinical dataset. After a single administration of HEAL-101, we edited up to 70% of the APOC3 gene, with activity restricted to the liver, and consistently reduced triglycerides by 76% in a disease model. Taken together, these results strengthen our confidence in HEAL-101 as we continue to advance the program toward the clinic. Adrian will walk you through the details in a moment.
Frequently Asked Questions About CLLS
Did CLLS beat earnings estimates last quarter?
Yes. Cellectis SA reported EPS of $0.01 for the quarter ended Sep 30, 2026, above the -$0.21 estimate, a 104.76% surprise.
What EPS do analysts expect from CLLS next quarter?
The consensus EPS estimate for Cellectis SA for the quarter ending Dec 31, 2026 is -$0.18 from 7 analysts, with estimates from -$0.26 to -$0.12.
How often does CLLS beat earnings estimates?
Cellectis SA beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +19.43%.
CLLS pages: Overview, Earnings, Forecast, Financials, Competitors